Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUYOC8)

Drug Name

AP12009 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[1]

Therapeutic Class

Antisense

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transforming growth factor beta 2 (TGFB2)	TTY9TWO	TGFB2_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Transforming growth factor beta 2 (TGFB2)	DTT	TGFB2	5.307	4.868	4.76	5.406

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Colorectal cancer

ICD Disease Classification

2B91.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Transforming growth factor beta 2 (TGFB2)	DTT	TGFB2	9.75E-02	0.41	1.1

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT00761280) Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma. U.S. National Institutes of Health.
2	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.